Article Archive for 5 June 2009
Santaris Pharma announced that the cancer drug EZN-2968 - an inhibitor of HIF-1alpha, jointly developed by Enzon Pharmaceuticals and Santaris Pharma A/S - was well tolerated and showed early signs of clinical benefit in previously …
ACCESS PHARMACEUTICALS, INC. (OTC Bulletin Board: ACCP), announced that new Thiarabine preclinical efficacy data will shortly be published demonstrating that thiarabine combined with clofarabine provides much greater antitumor activity than achieved by either agent alone. …
Roche announced that oral and poster presentations highlighting results from the extensive multi-national ACTEMRA(R) (tocilizumab) clinical development program will be presented at the 10th Annual Congress of the European League Against Rheumatism (EULAR), which will …
Novavax, Inc. (Nasdaq: NVAX) and the Division of Microbiology and Infectious Diseases (DMID) of the National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health (NIH) have signed an agreement to cooperate …
Abbott (NYSE: ABT) and AstraZeneca announced that the companies have submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for an investigational compound for the treatment of mixed dyslipidemia, …
